Since ANKLE1, EMD, and LEMD2 expression levels were mainly associated with CD56bright NK cells, it is inferred that these genes enriched in resting CD56bright NK cells of PRAD patients had a poor prognosis, which needs to be further validated by bioassays. This evidence concerns the gene ANKLE1 and prostate adenocarcinoma.